Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The AML16 trial evaluated the combination of the farnesyltransferase inhibitor, tipifarnib, and low dose cytarabine (LDAC) in older acute myeloid leukaemia (AML) patients in a 'Pick a Winner' design. The aim was to double remission rates compared to LDAC, with initial evaluation after 100 patients. Failure to improve remission would result in discontinuation. A total of 65 patients, median age 74 years (range 62-86), were randomized. After reviewing the first 45 patients, the Data Monitoring Committee concluded that the overall aspirations would not be met and recommended closure. The addition of tipifarnib had no effect on response, toxicity or survival.

Original publication

DOI

10.1111/j.1365-2141.2012.09165.x

Type

Journal article

Journal

Br J Haematol

Publication Date

08/2012

Volume

158

Pages

519 - 522

Keywords

Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Enzyme Inhibitors, Farnesyltranstransferase, Female, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Quinolones, Survival Analysis, Treatment Outcome